Since 1995 our team has participated in the
development of > 50 Strategic Marketing Plans.

We have developed and implemented over:

  • 80 Accredited Educational Programs
  • 115 Advisory Boards
  • 75 Publications
  • 45 Experience Trials and Clinical Research Projects
  • 2 book chapters
  • 6 practice guidelines
  • 110 Market Research Projects (including proprietary touchscreen system)

In addition, our studies have been covered and cited by Managed Care Consultant-First Report,, Medscape, and others.

Year Manuscripts Published Presentations Made/Scheduled Abstracts Accepted
Pre-2005 6
2005 2 11 11
2006 4 16 17
2007 5 10 12
2008 2 14 11
2009 7 9 14
2010 11 5 5
2011 3 3 3
2012 4 4 5
2013 1 10 10
2014 1 7 2
2015 1 6 7
In review process 3 4 1

Recent Publications Include:

  • Annual Incremental Health Benefit Costs and Absenteeism Among Employees with and Without Rheumatoid Arthritis. JOEM. March 2013; 55(3):240-244.
  • Absenteeism and Productivity Impact of Treatment Among Employees with Hepatitis-C. Am J Manag Care. 2011 Oct:17(10):657-64.
  • Comparing costs and absences for Multiple Sclerosis among US employees: pre- and post-treatment initiation.Curr Med Res Opin. 2011 Jan;27(1):179–88.
  • Excess Comorbidity Prevalence and Costs Associated with Functional Dyspepsia in an Employed Population. Dig Dis Sci. 2011
  • Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin. 2010: 26(12): 2813–21
  • Human Capital Costs and Absenteeism among Employees with Various Conditions (Book Chapter, publication 11/11)
  • Objectively Measured Work Output (Productivity) among Employees with Various Health Conditions (Book Chapter, publication 11/11)
  • Baran RW, Samp JC, Walker DR, Smeeding JE, Young JW, Kleinman NL, Brook RA.  Costs and absence of HCV-infected employees by disease stage. J Med Econ. 2015 Jun 5:1-13. [Epub ahead of print]
  • Brook RA, Kleinman NL, Patel S, Smeeding JE, Beren IA, Turpcu A. United States comparative costs and absenteeism of diabetic ophthalmic conditions. Postgrad Med. 2014 Dec 31:1-8.
  • Brook RA, Young JW, Smeeding JE3, Velez FF. Progression to Adjunctive Therapy Among Commercially-Insured Patients with Partial-Onset Epilepsy. Poster #20-M, presented at the ASHP Summer Meeting; June 6-10, 2015; Denver, CO, USA.

Recent projects include:

Retrospective database studies:
  • Costs and Absence of HCV-Infected Employees by Disease Stage
  • Comparative Health Benefit Costs of Employees with Diabetic Macular Edema, Diabetic Retinopathy, or Diabetes Versus No Diabetes in the United States.
  • Comparing the costs, absences, and adherence of products used to treat chronic conditions such as multiple sclerosis, rheumatoid arthritis, depression, diabetes, and others.
  • Focused on the incremental impact of various conditions on employees, using annual study timeframes, pre-/post designs, and others.
  • Examining the costs, prevalence, and services of standardized comorbidity categories associated with various conditions.
  • Comparisons of Fixed Dose Combination products with Lose Dose Combination products on costs, absence, and patient persistence with therapies.
  • Research on the impact of add-back therapy on patient compliance in persons with Endometriosis.
  • The impact of plan design and co-pays on patient persistence and adherence with therapies.
  • Using Medicaid data, annual timeframes, and pre-/post designs.
  • Clinical and Payor Advisory board programs for new and developmental products.

A 1250 patient / 300 physician launch study rolled out within 90 days of FDA approval (including legal/regulatory approval and all aspects of study design). Over 80% of the final (1 month) data was input, Q/A'd, and analyzed within 90 days of initial roll-out. This study also captured competitive market share. Conference papers were created as well.

A 9000 patient / 250 hospital observational study related to Community Acquired Pneumonia. Hospitals are given a report benchmarking their outcomes compared to the other sites participating in the study. Aggregate data is provided to the study sponsor on a regular basis, comparing their drug to competitors.

An IVR (Interactive Voice Response) telephonic system capturing outcomes and prescription utilization information weekly from 150 patients over a 12 month period. Regular compliance has been obtained in 85% of the patients enrolled. Our IVR system is used in five languages in four countries.

A market research program has been conducted at major medical conferences, capturing physician opinions and practice/prescribing patterns over the last six years. Typically 300-400 physicians are surveyed per conference. Reporting, including complete statistics, is typically done within a 48 hour turnaround.

Our expert advisory panels have helped lend credibility, and brought objective scientific knowledge to our client's marketing presentations. This in turn has streamlined the formulary approval process for our client's recently approved drugs.

An integrated 'Turn-Key' medical marketing campaign for a small pharma company, consisting of strategic consulting, expert speaker selection, a series of medical and pharmacist advisory boards, market research, sales training, and Phase IV research